181 related articles for article (PubMed ID: 35445726)
21. Prospective study of germline genetic testing in incident cases of pancreatic adenocarcinoma.
Brand R; Borazanci E; Speare V; Dudley B; Karloski E; Peters MLB; Stobie L; Bahary N; Zeh H; Zureikat A; Hogg M; Lee K; Tsung A; Rhee J; Ohr J; Sun W; Lee J; Moser AJ; DeLeonardis K; Krejdovsky J; Dalton E; LaDuca H; Dolinsky J; Colvin A; Lim C; Black MH; Tung N
Cancer; 2018 Sep; 124(17):3520-3527. PubMed ID: 30067863
[TBL] [Abstract][Full Text] [Related]
22. PanGen-Fam: Spanish registry of hereditary pancreatic cancer.
Mocci E; Guillen-Ponce C; Earl J; Marquez M; Solera J; Salazar-López MT; Calcedo-Arnáiz C; Vázquez-Sequeiros E; Montans J; Muñoz-Beltrán M; Vicente-Bártulos A; González-Gordaliza C; Sanjuanbenito A; Guerrero C; Mendía E; Lisa E; Lobo E; Martínez JC; Real FX; Malats N; Carrato A
Eur J Cancer; 2015 Sep; 51(14):1911-7. PubMed ID: 26212471
[TBL] [Abstract][Full Text] [Related]
23. Germline mutations in Japanese familial pancreatic cancer patients.
Takai E; Yachida S; Shimizu K; Furuse J; Kubo E; Ohmoto A; Suzuki M; Hruban RH; Okusaka T; Morizane C; Furukawa T
Oncotarget; 2016 Nov; 7(45):74227-74235. PubMed ID: 27732944
[TBL] [Abstract][Full Text] [Related]
24. High Prevalence of Hereditary Cancer Syndromes and Outcomes in Adults with Early-Onset Pancreatic Cancer.
Bannon SA; Montiel MF; Goldstein JB; Dong W; Mork ME; Borras E; Hasanov M; Varadhachary GR; Maitra A; Katz MH; Feng L; Futreal A; Fogelman DR; Vilar E; McAllister F
Cancer Prev Res (Phila); 2018 Nov; 11(11):679-686. PubMed ID: 30274973
[No Abstract] [Full Text] [Related]
25. Outcome of Pancreatic Cancer Surveillance Among High-Risk Individuals Tested for Germline Mutations in
Saldia A; Olson SH; Nunes P; Liang X; Samson ML; Salo-Mullen E; Marcell V; Stadler ZK; Allen PJ; Offit K; Kurtz RC
Cancer Prev Res (Phila); 2019 Sep; 12(9):599-608. PubMed ID: 31337648
[TBL] [Abstract][Full Text] [Related]
26. Referral frequency, attrition rate, and outcomes of germline testing in patients with pancreatic adenocarcinoma.
Walker EJ; Carnevale J; Pedley C; Blanco A; Chan S; Collisson EA; Tempero MA; Ko AH
Fam Cancer; 2019 Apr; 18(2):241-251. PubMed ID: 30267352
[TBL] [Abstract][Full Text] [Related]
27. Epidemiology and geographic distribution of BRCA1-2 and DNA Damage response genes pathogenic variants in pancreatic ductal adenocarcinoma patients.
Macchini M; Centonze F; Peretti U; Orsi G; Militello AM; Valente MM; Cascinu S; Reni M
Cancer Treat Rev; 2022 Mar; 104():102357. PubMed ID: 35184001
[TBL] [Abstract][Full Text] [Related]
28. Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer.
Hu C; Hart SN; Polley EC; Gnanaolivu R; Shimelis H; Lee KY; Lilyquist J; Na J; Moore R; Antwi SO; Bamlet WR; Chaffee KG; DiCarlo J; Wu Z; Samara R; Kasi PM; McWilliams RR; Petersen GM; Couch FJ
JAMA; 2018 Jun; 319(23):2401-2409. PubMed ID: 29922827
[TBL] [Abstract][Full Text] [Related]
29. Prevalence of Germline Pathogenic Variants in Cancer Predisposing Genes in Czech and Belgian Pancreatic Cancer Patients.
Wieme G; Kral J; Rosseel T; Zemankova P; Parton B; Vocka M; Van Heetvelde M; Kleiblova P; Blaumeiser B; Soukupova J; van den Ende J; Nehasil P; Tejpar S; Borecka M; Gómez García EB; Blok MJ; Safarikova M; Kalousova M; Geboes K; De Putter R; Poppe B; De Leeneer K; Kleibl Z; Janatova M; Claes KBM
Cancers (Basel); 2021 Sep; 13(17):. PubMed ID: 34503238
[TBL] [Abstract][Full Text] [Related]
30. Identification of genetic risk for pancreatic adenocarcinoma.
Flores K; Dinh K; Rouleau E; Whalen G; Wassef W; LaFemina J
Cancer Genet; 2015 Nov; 208(11):559-63. PubMed ID: 26481832
[TBL] [Abstract][Full Text] [Related]
31. Deleterious Germline Mutations in Patients With Apparently Sporadic Pancreatic Adenocarcinoma.
Shindo K; Yu J; Suenaga M; Fesharakizadeh S; Cho C; Macgregor-Das A; Siddiqui A; Witmer PD; Tamura K; Song TJ; Navarro Almario JA; Brant A; Borges M; Ford M; Barkley T; He J; Weiss MJ; Wolfgang CL; Roberts NJ; Hruban RH; Klein AP; Goggins M
J Clin Oncol; 2017 Oct; 35(30):3382-3390. PubMed ID: 28767289
[TBL] [Abstract][Full Text] [Related]
32. Prevalence of Pathogenic Mutations in Cancer Predisposition Genes among Pancreatic Cancer Patients.
Hu C; Hart SN; Bamlet WR; Moore RM; Nandakumar K; Eckloff BW; Lee YK; Petersen GM; McWilliams RR; Couch FJ
Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):207-11. PubMed ID: 26483394
[TBL] [Abstract][Full Text] [Related]
33. Implications of Multigene Panel Testing on Psychosocial Outcomes: A Comparison of Patients With Pancreatic and Breast or Ovarian Cancer.
Koptiuch C; Espinel WF; Kohlmann WK; Zhao J; Kaphingst KA
JCO Precis Oncol; 2021; 5():. PubMed ID: 34250392
[TBL] [Abstract][Full Text] [Related]
34. Identification of germline genetic mutations in patients with pancreatic cancer.
Salo-Mullen EE; O'Reilly EM; Kelsen DP; Ashraf AM; Lowery MA; Yu KH; Reidy DL; Epstein AS; Lincoln A; Saldia A; Jacobs LM; Rau-Murthy R; Zhang L; Kurtz RC; Saltz L; Offit K; Robson ME; Stadler ZK
Cancer; 2015 Dec; 121(24):4382-8. PubMed ID: 26440929
[TBL] [Abstract][Full Text] [Related]
35. Hereditary vs Familial Pancreatic Cancer: Associated Genetic Syndromes and Clinical Perspective.
Copur MS; Talmon GA; Wedel W; Hart JD; Merani S; Vargasi LM
Oncology (Williston Park); 2020 Jun; 34(6):196-201. PubMed ID: 32609864
[TBL] [Abstract][Full Text] [Related]
36. Germline variants in cancer-predisposing genes in pancreatic cancer patients with a family history of cancer.
Terashima T; Morizane C; Ushiama M; Shiba S; Takahashi H; Ikeda M; Mizuno N; Tsuji K; Yasui K; Azemoto N; Satake H; Nomura S; Yachida S; Sugano K; Furuse J
Jpn J Clin Oncol; 2022 Oct; 52(10):1105-1114. PubMed ID: 36135357
[TBL] [Abstract][Full Text] [Related]
37. Family communication and patient distress after germline genetic testing in individuals with pancreatic ductal adenocarcinoma.
Peters MLB; Stobie L; Dudley B; Karloski E; Allen K; Speare V; Dolinsky JS; Tian Y; DeLeonardis K; Krejdovsky J; Button A; Lim C; Borazanci E; Brand R; Tung N
Cancer; 2019 Jul; 125(14):2488-2496. PubMed ID: 30980401
[TBL] [Abstract][Full Text] [Related]
38. Surveillance Outcome and Genetic Findings in Individuals at High Risk of Pancreatic Cancer.
Rosner G; Scapa E; Ziv T; Gluck N; Ben-Yehoyada M
Clin Transl Gastroenterol; 2024 Feb; 15(2):e00668. PubMed ID: 38147532
[TBL] [Abstract][Full Text] [Related]
39. Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer.
Couch FJ; Shimelis H; Hu C; Hart SN; Polley EC; Na J; Hallberg E; Moore R; Thomas A; Lilyquist J; Feng B; McFarland R; Pesaran T; Huether R; LaDuca H; Chao EC; Goldgar DE; Dolinsky JS
JAMA Oncol; 2017 Sep; 3(9):1190-1196. PubMed ID: 28418444
[TBL] [Abstract][Full Text] [Related]
40. Germline sequence analysis of RABL3 in a large series of pancreatic ductal adenocarcinoma patients reveals no evidence of deleterious variants.
Roberts NJ; Grant RC; Gallinger S; Klein AP;
Genes Chromosomes Cancer; 2021 Aug; 60(8):559-564. PubMed ID: 33724601
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
